Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform
Details : Through the agreement, Merck will support Afrigen in advancing the development of an mRNA vaccine technology platform, scaling up production, optimizing processes & provide troubleshooting expertise.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Evaxion Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims at developing a novel, prophylactic, mRNA vaccine, EVX-B2, based on Evaxion’s EDEN™ platform, a proprietary AI platform capable of rapidly identifying those antigens that will trigger a highly protective immune response, to dis...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Evaxion Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : mRNA Based SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Curapath
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Curapath will be responsible for development of a scaled-up manufacturing process of the nanoparticle formulation for the m-RNA based vaccine and will assist in developing the fill/finish process.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : mRNA Based SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Curapath
Deal Size : Undisclosed
Deal Type : Collaboration